Karen Esq - Intracellular Senior Officer
| ITCI Stock | USD 71.81 0.49 0.68% |
Executive
Karen Esq is Senior Officer of Intracellular Th
| Age | 62 |
| Address | 430 East 29th Street, New York, NY, United States, 10016 |
| Phone | 646 440 9333 |
| Web | https://www.intracellulartherapies.com |
Intracellular Management Efficiency
The company has return on total asset (ROA) of (0.1343) % which means that it has lost $0.1343 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2239) %, meaning that it created substantial loss on money invested by shareholders. Intracellular's management efficiency ratios could be used to measure how well Intracellular manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.2. The current Return On Capital Employed is estimated to decrease to -0.28. As of now, Intracellular's Non Currrent Assets Other are increasing as compared to previous years. The Intracellular's current Deferred Long Term Asset Charges is estimated to increase to about 635.1 K, while Total Assets are projected to decrease to under 410.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Timothy Brown | HP Inc | 57 | |
| David MD | Amgen Inc | 61 | |
| Jason Arnold | Air Lease | N/A | |
| Marie Myers | HP Inc | 56 | |
| Sara Evans | Air Lease | N/A | |
| Robert Binns | HP Inc | 46 | |
| Wayne Borduin | Chevron Corp | N/A | |
| Courtney McKeown | Air Lease | N/A | |
| Allyson Park | Walmart | N/A | |
| Justin Claeys | Amgen Inc | N/A | |
| James MD | Amgen Inc | 52 | |
| Stephanie Wissink | Walmart | N/A | |
| Harvey Anderson | HP Inc | 49 | |
| Ryan McKenna | Air Lease | N/A | |
| Todd Levy | Chevron Corp | N/A | |
| Frank Mount | Chevron Corp | N/A | |
| Nancy Grygiel | Amgen Inc | 56 | |
| Daniel Verwholt | Air Lease | N/A | |
| Alan Russell | Amgen Inc | N/A | |
| Jeff Gustavson | Chevron Corp | 51 | |
| Antonio Lucio | HP Inc | 65 | |
Management Performance
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 |
Intracellular Th Leadership Team
Elected by the shareholders, the Intracellular's board of directors comprises two types of representatives: Intracellular inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Intracellular. The board's role is to monitor Intracellular's management team and ensure that shareholders' interests are well served. Intracellular's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Intracellular's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Lawrence Wennogle, Vice President of Drug Discovery | ||
| Suresh Durgam, Senior Vice President Late Stage Clinical Development and Medical Affairs | ||
| Michael Rawlins, Director | ||
| Robert Nostrand, Independent Director | ||
| Richard Lerner, Director | ||
| Allen Fienberg, Co-Founder and VP of Bus. Devel. | ||
| Suresh MD, Executive Officer | ||
| Willie MD, Senior Development | ||
| Lawrence CPA, CFO, Finance | ||
| Kimberly Vanover, VP of Clinical Devel. | ||
| Michael Olchaskey, Senior Vice President Head of Regulatory Affairs | ||
| CPA CPA, CFO, Fin | ||
| Christopher Alafi, Director | ||
| Robert Davis, Senior Vice President and Chief Scientific Officer | ||
| Mark Neumann, Executive Vice President Chief Commercial Officer | ||
| Karen Esq, Senior Officer | ||
| Michael Halstead, Sr. VP, General Counsel and Secretary | ||
| Sharon Mates, Co-Founder, Chairman, CEO and Pres | ||
| Andrew Satlin, Executive Vice President and Chief Medical Officer | ||
| Michael JD, General VP | ||
| Juan Sanchez, Vice President - Corporate Communications and Investor Relations | ||
| Rory Riggs, Independent Director | ||
| John Bardi, Senior Vice President - Market Access, Policy and Government Affairs | ||
| Joel Marcus, Director | ||
| Lawrence Hineline, Vice President and CFO |
Intracellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Intracellular a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 6.52 B | ||||
| Shares Outstanding | 105.36 M | ||||
| Shares Owned By Insiders | 2.35 % | ||||
| Shares Owned By Institutions | 92.11 % | ||||
| Number Of Shares Shorted | 3.59 M | ||||
| Price To Earning | (6.56) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Intracellular Th information on this page should be used as a complementary analysis to other Intracellular's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Intracellular Stock analysis
When running Intracellular's price analysis, check to measure Intracellular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intracellular is operating at the current time. Most of Intracellular's value examination focuses on studying past and present price action to predict the probability of Intracellular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intracellular's price. Additionally, you may evaluate how the addition of Intracellular to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |
Is Intracellular's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Revenue Per Share 4.843 | Quarterly Revenue Growth 0.503 | Return On Assets (0.13) | Return On Equity (0.22) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.